[Impacts that dimethoate inhibited the benchmark dose of acetylcholinesterase based on experimental designs]
Xiansong He1, Tingting Li1, Nannan Yi1
1Key Laboratory of Medical Engineering Environment, Depart of Nutrition and Food Hygiene, School of Public Health, Southeast University, Nanjing 210009, China.
Objective:
To obtain the impacts of experimental design on benchmark dose (BMD), and the result was applied to test the computer simulation by software Slob (optimal method to calculate the BMD: for a certain sample capacity, to add the experimental groups by reducing the amount of animals in each group) , consequently, this method can be widely used in the future.
Methods:
Eighty adult female SD rats were ig given dimethoate 0.5, 1, 2, 4, 8, 16 and 32 mg/kg for 21 d, respectively. Rats were sacrificed, and acetylcholinesterase (AChE) activity in the hippocampus, cerebral cortex and serum of rats was determined after dimethoate was ig given to rats for 21 d. And then, the software package PROAST28.1 was applied to calculate the BMD. The four does groups of 10 animals (4 x 10 design) and 8 x 5 design were selected from 8 x 10 design to study the impacts of experimental design on BMD.
Results:
Comparing with the normal control, the significant decline of AChE in hippocampus was observed in 2, 4, 8, 16 and 32 mg/kg groups (P < 0.05), whereas the significant decrease was obtained in 0.5, 1, 2, 4, 8, 16 and 32 mg/kg groups (P < 0.05). Taking the 8 x 10 design as the standard, the confidence interval of BMD calculated by both of 4 x 10 design and 8 x 5 design covered the BMD by 8 x 10 design. And also, confidence interval of BMD, calculated by design scheme 1, 2, 3, 4 and 6 of 4 x 10 design, wider than that of 8 x 5 design, but its scheme 5 narrower than 8 x 5 design.
Conclusion:
To add experimental groups in a certain sample capacity was the optimal method to calculate BMD, but was not the common toxicity experimental design (e. g. set four groups including control, low-dose, moderate-dose, high-dose group).
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...


